Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Acquired by Graham Capital Management L.P.

Graham Capital Management L.P. lifted its position in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 8.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 18,634 shares of the company’s stock after buying an additional 1,453 shares during the quarter. Graham Capital Management L.P.’s holdings in Stoke Therapeutics were worth $206,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of STOK. KLP Kapitalforvaltning AS purchased a new stake in Stoke Therapeutics during the fourth quarter worth about $63,000. Teacher Retirement System of Texas purchased a new stake in Stoke Therapeutics during the 4th quarter worth approximately $113,000. China Universal Asset Management Co. Ltd. acquired a new stake in Stoke Therapeutics during the 4th quarter worth approximately $124,000. Tower Research Capital LLC TRC lifted its holdings in Stoke Therapeutics by 70.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock worth $132,000 after buying an additional 4,918 shares in the last quarter. Finally, Invesco Ltd. purchased a new position in Stoke Therapeutics in the 4th quarter valued at approximately $133,000.

Insiders Place Their Bets

In related news, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the sale, the director now directly owns 148,253 shares in the company, valued at $1,285,353.51. This trade represents a 6.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Barry Ticho sold 3,884 shares of the business’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the sale, the insider now directly owns 63,962 shares of the company’s stock, valued at approximately $554,550.54. This trade represents a 5.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,532 shares of company stock valued at $143,332. 11.30% of the stock is owned by corporate insiders.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock opened at $9.76 on Monday. The stock has a market cap of $532.87 million, a PE ratio of -4.65 and a beta of 1.20. The stock’s fifty day moving average is $8.16 and its two-hundred day moving average is $9.94. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.38. The business had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. On average, research analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

STOK has been the topic of a number of recent research reports. Chardan Capital reaffirmed a “buy” rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Cantor Fitzgerald upgraded Stoke Therapeutics to a “strong-buy” rating in a report on Wednesday, May 14th. HC Wainwright decreased their price objective on Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, May 14th. Finally, Needham & Company LLC reissued a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $23.20.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.